1Hannon, RA & Eastell, R (2003) Biochemical markers of bone turnover and fracture prediction. J Br Menopause Soc 9, 10–15.
2Garnero, P & Delmas, PD (2004) Contribution of bone mineral density and bone turnover markers to the estimation of risk of osteoporotic fracture in postmenopausal women. J Musculoskelet Neuronal Interact 4, 50–63.
3De Laet, C, Kanis, JA, Oden, A, et al. (2005) Body mass index as a predictor of fracture risk: a meta-analysis. Osteoporos Int 16, 1330–1338.
4Kanis, JA, Borgstrom, F, Zethraeus, N, Johnell, O, Oden, A & Jonsson, B (2005) Intervention thresholds for osteoporosis in the UK. Bone 36, 22–32.
5Borgstrom, F, Johnell, O, Kanis, JA, Jonsson, B & Rehnberg, C (2006) At what hip fracture risk is it cost-effective to treat? International intervention thresholds for the treatment of osteoporosis. Osteoporos Int 17, 1459–1471.
6Heikkinen, J, Vaheri, R & Timonen, U (2006) A 10-year follow-up of postmenopausal women on long-term continuous combined hormone replacement therapy: update of safety and quality-of-life findings. J Br Menopause Soc 12, 115–125.
7Nelson, HD, Humphrey, LL, Nygren, P, Teutsch, SM & Allan, JD (2002) Postmenopausal hormone replacement therapy: scientific review. JAMA 288, 872–881.
8Reed, SD, Newton, KM & Lacroix, AZ (2004) Indications for hormone therapy: the post-Women's Health Initiative era. Endocrinol Metab Clin North Am 33, 691–715.
9Whitehead, M & Farmer, R (2004) The million women study: a critique. Endocrine 24, 187–193.
10NIH Consensus Conference (2005) NIH State-of-the-Science Conference Statement on management of menopause-related symptoms. NIH Consensus State-of-the-Science Statements 22, 1–38.
11Stevenson, JC (2006) HRT, osteoporosis and regulatory authorities Quis custodiet ipsos custodes? Human Reprod 21, 1668–1671.
12Rossouw, JE, Anderson, GL, Prentice, RL, et al. (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288, 321–333.
13Udell, JA, Fischer, MA, Brookhart, MA, Solomon, DH & Choudhry, NK (2006) Effect of the Women's Health Initiative on osteoporosis therapy and expenditure in Medicaid. J Bone Miner Res 21, 765–771.
14Usher, C, Teeling, M, Bennett, K & Feely, J (2006) Effect of clinical trial publicity on HRT prescribing in Ireland. Eur J Clin Pharmacol 62, 307–310.
15Guay, MP, Dragomir, A, Pilon, D, Moride, Y & Perreault, S (2007) Changes in pattern of use, clinical characteristics and persistence rate of hormone replacement therapy among postmenopausal women after the WHI publication. Pharmacoepidemiol Drug Safety 16, 17–27.
16Chapuy, MC, Arlot, ME, Duboeuf, F, et al. (1992) Vitamin D3 and calcium to prevent hip fractures in the elderly women. N Engl J Med 327, 1637–1642.
17Chevalley, T, Rizzoli, R, Nydegger, V, et al. (1994) Effects of calcium supplements on femoral bone mineral density and vertebral fracture rate in vitamin-D-replete elderly patients. Osteoporos Int 4, 245–252.
18Recker, RR, Hinders, S, Davies, KM, et al. (1996) Correcting calcium nutritional deficiency prevents spine fractures in elderly women. J Bone Miner Res 11, 1961–1966.
19Dawson-Hughes, B, Harris, SS, Krall, EA & Dallal, GE (1997) Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med 337, 670–676.
20Shea, B, Wells, G, Cranney, A, et al. (2002) Meta-analyses of therapies for postmenopausal osteoporosis. VII. Meta-analysis of calcium supplementation for the prevention of postmenopausal osteoporosis. Endocr Rev 23, 552–559.
21Boonen, S, Bischoff-Ferrari, HA, Cooper, C, et al. (2006) Addressing the musculoskeletal components of fracture risk with calcium and vitamin D: a review of the evidence. Calcif Tissue Int 78, 257–270.
22Rossini, M, Bianchi, G, Di Munno, O, et al. (2006) Determinants of adherence to osteoporosis treatment in clinical practice. Osteoporos Int 17, 914–921.
23Downey, TW, Foltz, SH, Boccuzzi, SJ, Omar, MA & Kahler, KH (2006) Adherence and persistence associated with the pharmacologic treatment of osteoporosis in a managed care setting. South Med J 99, 570–575.
24Boonen, S, Rizzoli, R, Meunier, PJ, et al. (2004) The need for clinical guidance in the use of calcium and vitamin D in the management of osteoporosis: a consensus report. Osteoporos Int 15, 511–519.
25Bonjour, JP, Schurch, MA, Chevalley, T, Ammann, P & Rizzoli, R (1997) Protein intake, IGF-1 and osteoporosis. Osteoporos Int 7, Suppl. 3, S36–S42.
26Munger, RG, Cerhan, JR & Chiu, BC (1999) Prospective study of dietary protein intake and risk of hip fracture in postmenopausal women. Am J Clin Nutr 69, 147–152.
27Hannan, MT, Tucker, KL, Dawson-Hughes, B, Cupples, LA, Felson, DT & Kiel, DP (2000) Effect of dietary protein on bone loss in elderly men and women: the Framingham Osteoporosis Study. J Bone Miner Res 15, 2504–2512.
28Bonjour, JP (2005) Dietary protein: an essential nutrient for bone health. J Am Coll Nutr 24, Suppl., 526S–536S.
29Rogers, A, Hannon, RA & Eastell, R (2000) Biochemical markers as predictors of rates of bone loss after menopause. J Bone Miner Res 15, 1398–1404.
30Chapurlat, RD, Garnero, P, Breart, G, Meunier, PJ & Delmas, PD (2000) Serum type I collagen breakdown product (serum CTX) predicts hip fracture risk in elderly women: the EPIDOS study. Bone 27, 283–286.
31Bruyere, O, Collette, J, Delmas, P, et al. (2003) Interest of biochemical markers of bone turnover for long-term prediction of new vertebral fracture in postmenopausal osteoporotic women. Maturitas 44, 259–265.
32Ravn, P, Thompson, DE, Ross, PD & Christiansen, C (2003) Biochemical markers for prediction of 4-year response in bone mass during bisphosphonate treatment for prevention of postmenopausal osteoporosis. Bone 33, 150–158.
33Grados, F, Brazier, M, Kamel, S, et al. (2003) Prediction of bone mass density variation by bone remodeling markers in postmenopausal women with vitamin D insufficiency treated with calcium and vitamin D supplementation. J Clin Endocrinol Metab 88, 5175–5179.
34Bauer, DC, Black, DM, Garnero, P, et al. (2004) Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial. J Bone Miner Res 19, 1250–1258.
35World Health Organization (1994) Assessment of Fracture Risk and its Application to Screening for Postmenopausal Osteoporosis. . Geneva: WHO.
36Baecke, JA, Burema, J & Frijters, JE (1982) A short questionnaire for the measurement of habitual physical activity in epidemiological studies. Am J Clin Nutr 36, 936–942.
37Favier, JC, Ireland-Ripert, J, Toque, C & Feinberg, M (1995) Répertoire Général des Aliments. Table de Composition, 2nd ed.Paris: INRA.
38Brandolini, M, Gueguen, L, Boirie, Y, Rousset, P, Bertiere, MC & Beaufrere, B (2005) Higher calcium urinary loss induced by a calcium sulphate-rich mineral water intake than by milk in young women. Br J Nutr 93, 225–231.
39Gascoin-Lachambre, G, Trivin, C, Brauner, R & Souberbielle, JC (2007) Serum procollagen type 1 amino-terminal propeptide (P1NP) as an early predictor of the growth response to growth hormone treatment: comparison of intrauterine growth retardation and idiopathic short stature. Growth Horm IGF Res 17, 194–200.
40Hollis, BW, Kamerud, JQ, Selvaag, SR, Lorenz, JD & Napoli, JL (1993) Determination of vitamin D status by radioimmunoassay with an 125I-labeled tracer. Clin Chem 39, 529–533.
41Dawson-Hughes, B, Heaney, RP, Holick, MF, Lips, P, Meunier, PJ & Vieth, R (2005) Estimates of optimal vitamin D status. Osteoporos Int 16, 713–716.
42Walton, RJ & Bijvoet, OL (1977) A simple slide-rule method for the assessment of renal tubular reaborption of phosphate in man. Clin Chim Acta 81, 273–276.
43Buchs, B, Rizzoli, R & Bonjour, JP (1991) Evaluation of bone resorption and renal tubular reabsorption of calcium and phosphate in malignant and nonmalignant hypercalcemia. Bone 12, 47–56.
44Bonjour, JP, Philippe, J, Guelpa, G, et al. (1988) Bone and renal components in hypercalcemia of malignancy and responses to a single infusion of clodronate. Bone 9, 123–130.
45Heaney, RP, McCarron, DA, Dawson-Hughes, B, et al. (1999) Dietary changes favorably affect bone remodeling in older adults. J Am Dietetic Assoc 99, 1228–1233.
46Meunier, PJ, Jenvrin, C, Munoz, F, de la Gueronniere, V, Garnero, P & Menz, M (2005) Consumption of a high calcium mineral water lowers biochemical indices of bone remodeling in postmenopausal women with low calcium intake. Osteoporos Int 16, 1203–1209.
47Storm, D, Eslin, R, Porter, ES, et al. (1998) Calcium supplementation prevents seasonal bone loss and changes in biochemical markers of bone turnover in elderly New England women: a randomized placebo-controlled trial. J Clin Endocrinol Metab 83, 3817–3825.
48Fardellone, P, Brazier, M, Kamel, S, et al. (1998) Biochemical effects of calcium supplementation in postmenopausal women: influence of dietary calcium intake. Am J Clin Nutr 67, 1273–1278.
49Palacios, S, Castelo-Branco, C, Cifuentes, I, et al. (2005) Changes in bone turnover markers after calcium-enriched milk supplementation in healthy postmenopausal women: a randomized, double-blind, prospective clinical trial. Menopause 12, 63–68.
50Kanis, JA, Johnell, O, Oden, A, Dawson, A, De Laet, C & Jonsson, B (2001) Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds. Osteoporos Int 12, 989–995.
51Kanis, JA, Johnell, O, Oden, A, et al. (2005) Intervention thresholds for osteoporosis in men and women: a study based on data from Sweden. Osteoporos Int 16, 6–14.
52Johnell, O, Kanis, JA, Oden, A, et al. (2005) Predictive value of BMD for hip and other fractures. J Bone Miner Res 20, 1185–1194.
53Kanis, JA, Johnell, O, De Laet, C, et al. (2004) A meta-analysis of previous fracture and subsequent fracture risk. Bone 35, 375–382.
54World Health Organization (2003) Prevention and Management of Osteoporosis. . Geneva: WHO.
55Kerstetter, JE, O'Brien, KO & Insogna, KL (2003) Dietary protein, calcium metabolism, and skeletal homeostasis revisited. Am J Clin Nutr 78, Suppl., 584S–592S.
56Heaney, RP (2001) The bone remodeling transient: interpreting interventions involving bone-related nutrients. Nutr Rev 59, 327–334.
57Dawson-Hughes, B & Harris, SS (2002) Calcium intake influences the association of protein intake with rates of bone loss in elderly men and women. Am J Clin Nutr 75, 773–779.
58Heaney, RP, Rafferty, K & Dowell, MS (2002) Effect of yogurt on a urinary marker of bone resorption in postmenopausal women. J Am Dietetic Assoc 102, 1672–1674.
59Aoe, S, Koyama, T, Toba, Y, Itabashi, A & Takada, Y (2005) A controlled trial of the effect of milk basic protein (MBP) supplementation on bone metabolism in healthy menopausal women. Osteoporos Int 16, 2123–2128.
60Garnero, P (2000) Markers of bone turnover for the prediction of fracture risk. Osteoporos Int 11, Suppl. 6, S55–S65.
61Lindsay, R, Gallagher, JC, Kleerekoper, M & Pickar, JH (2002) Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women. JAMA 287, 2668–26676.
62Delmas, PD, Bjarnason, NH, Mitlak, BH, et al. (1997) Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 37, 1641–1647.
63Meunier, PJ, Roux, C, Seeman, E, et al. (2004) The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 350, 459–468.
64Ettinger, B, Black, DM, Mitlak, BH, et al. (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 282, 637–645.
65Reginster, J, Minne, HW, Sorensen, OH, et al. (2000) Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 11, 83–91.
66Liberman, UA, Weiss, SR, Broll, J, et al. (1995) Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 333, 1437–1443.